

4/29/2020; Page 1

Suggested	Hydroxychloroquine Sulfate 100 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 008 654	1
-----------	---	-----	-----------	---

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Hydroxychloroquine Sulfate, USP	2.000	g				
Stevia Powder	0.20	g				
Glycerin, USP	5.0	mL				
Tutti Frutti Flavor	0.5	mL				
Medisca Oral Suspend (Suspending Vehicle)	50.0	mL				
Medisca Oral Syrup (Flavored Syrup Vehicle)	q.s. to 100.0	mL				

MERNOR

	N		MEDISCA [®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>		4/29/2020; Page 2
	Suggested				
	Formula		Sulfate 100 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 008 654
SP		EPARATORY CONSIL	DERATIONS		
	Light S	ensitive (protect from li	ght whenever possible): Hydroxychloroquine Sulfate	2	
			sture whenever possible): Stevia Powder, Glycerin		
	Suggested	Preparatory Guidelines			
		Non-Sterile Preparat	ion Sterile Preparation		
		rocessing Error / esting Considerations:	To account for processing error considerations during prepar measure an additional 5 to 9% of the required quantities of ing		00
	<u>S</u>	pecial Instruction:	This formula may contain one or more Active Pharmaceutical I may be classified as hazardous, please refer & verify the currer Antineoplastic and Other Hazardous Drugs in Healthcare Settin General Chapter <800> Hazardous Drugs – Handling in He informational and not compendially applicable unless otherwiss and enforcement bodies. For information on the scope, intended implementation context for USP General Chapter <800>, see: https://www.usp.org/usp-800-context-for-implementation- This formula must be prepared within the appropriate facilities environmental conditions, following the necessary guidelines a within USP 795 and USP 800, when handling hazardous drugs qualified personnel must prepare this formula.	nt NIOS ngs. At ealthca e speci d appli <u>fs.pdf</u> . under nd pro	SH list of this time, are Settings is fied by regulators cability, and adequate cedures as stated
			All required personal protective equipment (hazardous if applic limited to, lab coat, protective sleeves, gloves both inner and or dedicated shoe covers, hairnet, beard cover, eyewear, appropria and face shield, etc., where applicable must be worn at all time	uter if a ate face	applicable,
			If applicable, follow all required procedures for hazardous drug not limited to procurement, transport, storage, preparation, disp clean up (spills) & disposal.		
			If you are a registered 503B facility, please refer to all relevant including but not limited to the Code of Federal Regulations (C Industry (GFIs) and Compliance Policy Guides (CPGs).		
			This procedure requires the use of very small quantities of ingr and preparation techniques must be verified before dispensing		



4/29/2020; Page 3

Suggested Formula	Hydroxychloroquine Sulfate 100 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 008 654	
----------------------	---	-----	-----------	--

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Hydroxychloroquine Sulfate, USP§	2.000	g			
Stevia Powder §	0.20	g			
Glycerin, USP §	5.0	mL	(Q.)		
Tutti Frutti Flavor	0.5	mL	5		
Medisca Oral Suspend (Suspending Vehicle)	50.0	mL	N L		
Medisca Oral Syrup (Flavored Syrup Vehicle)	q.s. to 100.0	mL	0		

§ Weigh / measure just prior to use.

1.

2.

* Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction
Powder-liquid preparation:
A. Combine and triturate the following ingredients together to form a homogeneous powder blend:
-Hydroxychloroquine Sulfate -Stevia Powder
B. Levigate the homogeneous powder blend (Step 3A) with the Glycerin.
End result: Homogeneous liquid-like dispersion.
Medium Integration:
A. In the given order, sequentially add the following ingredients to the Oral Suspend (Suspending Vehicle):
-Tutti Frutti Flavor -Homogeneous powder blend (Step 1B)
Specifications: Continuously mix, using high-shear mixing techniques.
End result: Homogeneous liquid-like dispersion.
Note: Add the next ingredient, once the previous one has been completely added and dispersed.



4/29/2020; Page 4

	agested ormulaHydroxychloroquine Sulfate 100 mg/5 mL Oral Liquid (Suspension, 100 mL)FINF 008 654
3.	Filling to volume:
	A. Add Oral Syrup (Flavored Syrup Vehicle) to the mixture (Step 2A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).
	Specifications: Continuously mix, using high-shear mixing techniques.
	End result: Homogeneous liquid-like dispersion.
4.	Product transfer:
	A. Transfer the final product into the specified dispensing container (see "Packaging requirements").
	Note: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

+

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated, as per Packaging Requirements		 Tightly closed, light-resistant dispensing bottle. To be administered with a metered dose- measuring device.
	1	Shake well before use.	5	Use as directed. Do not exceed prescribed dose.
Auxiliary Labels	2	Keep refrigerated ($2^{\circ}C - 8^{\circ}C$). Do not freeze.	6	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Keep out of reach of children.	7	Cap tightly after use.
	4	May impair mental and/or physical ability. Use care when operating a car or machinery.	8	Protect from light.
Pharmacist Instructions Add any auxiliary labels specific to the active ingredient to the dispensing container as deemed neces			t to the dispensing container as deemed necessary.	
Patient Instructions Contact your pharmacist in the event of adverse reactions.				18.



4/29/2020; Page 5

Suggested Formula	Hydroxychloroquine Sulfate 100 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 008 654	
----------------------	---	-----	-----------	--

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.</i> American Pharmacists Association; 2016: 317.
2.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients,</i> 8 th Edition. American Pharmaceutical Association; 2017: 401.
3.	Hydroxychloroquine Sulfate (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4857.
4.	Hydroxychloroquine Sulfate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 655.
5.	Hydroxychloroquine Sulfate (Monograph). United States Pharmacopeia XLII / National Formulary 37. Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 2209.
6.	Hydroxychloroquine. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1677.
7.	USP <795>. United States Pharmacopeia XLII / National Formulary 37. Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 6951.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.